Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks

7. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Number of Hedge Fund Holders In Q3 2024: 55

Date of Cramer’s Comments: 8-28-24

Performance Since Then: -17.85%

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company that derives more than 90% of its sales through selling cystic fibrosis drugs. It also gained prominence earlier this year through its CASGEVY treatment which became the world’s first gene-editing-based treatment for Sickle Cell Disease. However, the latter half of 2024 has been nothing short of devastating for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s shares. The stock sank by 11% in December after the firm’s highly hyped non-addictive painkiller thought to have the potential to replace opioids failed to meet objectives. Here’s what Cramer said about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in August:

“I think Vertex is great. Look, its fibrosis franchise is incredible, and a terrible disease. But I also like the fact that what they’re doing in terms of opiates—look, this is a great company. No one ever talks about it. We’ve had them on. I think that they’re brilliant. Okay, per period. Down story.”